View ValuationBeacon Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Beacon Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 21Beacon Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 27, 2026Beacon Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 27, 2026お知らせ • Jan 22Beacon Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Beacon Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026お知らせ • Nov 07Beacon Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 11, 2025Beacon Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 11, 2025お知らせ • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.お知らせ • Oct 23Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025, at 11:00 Central Asia Standard Time. Location: hybrid platform., Bangladeshお知らせ • Oct 21Beacon Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 22, 2025Beacon Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 22, 2025お知らせ • Apr 23Beacon Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 20Beacon Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 29, 2025お知らせ • Oct 25Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024Beacon Pharmaceuticals PLC announced that they will report Q1, 2025 results on Oct 29, 2024Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Oct 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ৳113, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 50% over the past three years.お知らせ • Oct 01Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024, at 11:00 Central Asia Standard Time.お知らせ • Sep 19Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024Beacon Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Sep 29, 2024Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳137, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 37% over the past three years.Reported Earnings • May 18Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023)Third quarter 2024 results: ৳0.95 loss per share (further deteriorated from ৳0.037 loss in 3Q 2023). Revenue: ৳2.64b (up 23% from 3Q 2023). Net loss: ৳220.3m (loss widened ৳211.6m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 08Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024Beacon Pharmaceuticals PLC announced that they will report Q3, 2024 results on May 12, 2024New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (7.0% net profit margin).New Risk • Feb 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (7.0% net profit margin).お知らせ • Jan 30Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company SecretaryBeacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect.お知らせ • Jan 26Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Beacon Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024Reported Earnings • Jan 25First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023)First quarter 2024 results: EPS: ৳1.60 (up from ৳0.99 in 1Q 2023). Revenue: ৳2.32b (up 15% from 1Q 2023). Net income: ৳369.5m (up 62% from 1Q 2023). Profit margin: 16% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.Reported Earnings • Dec 07Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022)Full year 2023 results: EPS: ৳2.21 (down from ৳4.05 in FY 2022). Revenue: ৳8.51b (up 6.1% from FY 2022). Net income: ৳509.8m (down 46% from FY 2022). Profit margin: 6.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (101% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Profit margins are more than 30% lower than last year (8.6% net profit margin).Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).お知らせ • Nov 08Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023Beacon Pharmaceuticals PLC announced that they will report Q1, 2024 results on Nov 13, 2023お知らせ • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.お知らせ • Oct 24Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023, at 11:00 Bangladesh Standard Time.お知らせ • Oct 17Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023Beacon Pharmaceuticals PLC announced that they will report Q3, 2023 results on Oct 22, 2023お知らせ • Jun 20Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial OfficerBeacon Pharmaceuticals PLC announced that the Board of Directors has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023.お知らせ • May 12+ 1 more updateBeacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFOBeacon Pharmaceuticals PLC informed that Mr. Md. Abdul Haque Sarder, FCS, FCA, CFO of the company resigned from his position with effect from May 09, 2023.Reported Earnings • May 07Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022)Third quarter 2023 results: ৳0.037 loss per share (down from ৳0.99 profit in 3Q 2022). Revenue: ৳2.15b (up 16% from 3Q 2022). Net loss: ৳8.66m (down 104% from profit in 3Q 2022).Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.61 (up from ৳1.07 in 2Q 2022). Revenue: ৳2.19b (up 5.5% from 2Q 2022). Net income: ৳370.9m (up 51% from 2Q 2022). Profit margin: 17% (up from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Dec 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mohammad Sanaullah was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 24First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022)First quarter 2023 results: EPS: ৳0.99 (down from ৳1.52 in 1Q 2022). Revenue: ৳2.02b (down 11% from 1Q 2022). Net income: ৳228.8m (down 35% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.Valuation Update With 7 Day Price Move • Sep 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳315, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,087% over the past three years.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳320, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,040% over the past three years.Reported Earnings • May 22Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.99 (down from ৳2.01 in 3Q 2021). Revenue: ৳1.84b (down 29% from 3Q 2021). Net income: ৳228.9m (down 51% from 3Q 2021). Profit margin: 12% (down from 18% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 12Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.07 (up from ৳1.02 in 2Q 2021). Revenue: ৳2.08b (down 4.8% from 2Q 2021). Net income: ৳246.3m (up 5.1% from 2Q 2021). Profit margin: 12% (up from 11% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).Reported Earnings • Jun 24Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Feb 25New 90-day high: ৳103The company is up 50% from its price of ৳68.20 on 26 November 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.Is New 90 Day High Low • Feb 01New 90-day high: ৳84.30The company is up 5.0% from its price of ৳80.00 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.Is New 90 Day High Low • Nov 30New 90-day low: ৳66.50The company is down 17% from its price of ৳79.80 on 01 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Reported Earnings • Nov 26Third quarter 2020 earnings released: EPS ৳0.25The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 07Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020Beacon Pharmaceuticals Ltd. announced that they will report Q3, 2020 results on Jun 25, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Beacon Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:BEACONPHAR - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202514,7851,2387261,644N/A9/30/202513,8511,1328181,676N/A6/30/202512,5439477771,600N/A3/31/202512,2248452,0073,063N/A12/31/202411,5795701,4901,834N/A9/30/202411,184512-494351N/A6/30/202410,702521-1,300-180N/A3/31/20249,893466-3,559-1,622N/A12/31/20239,402662-1,817-193N/A9/30/20238,812651-697767N/A6/30/20238,510510-1,193621N/A3/31/20238,190699-7431,351N/A12/31/20227,887936-9301,484N/A9/30/20227,774812-1,0831,238N/A6/30/20228,023935-6371,082N/A3/31/20226,976936-479708N/A12/31/20217,7331,170-551180N/A9/30/20217,8391,158-226203N/A6/30/20217,121863-117197N/A3/31/20217,7191,007-59321N/A12/31/20206,493603-94249N/A9/30/20205,797396-22893N/A6/30/20205,591381-23291N/A3/31/20205,368115-399-235N/A12/31/20195,155104-57146N/A9/30/20194,919121N/A289N/A6/30/20194,647118N/A220N/A3/31/20194,564176N/A28N/A12/31/20184,281162N/A75N/A9/30/20183,917142N/A173N/A6/30/20183,761126N/A300N/A3/31/20183,295122N/A1,049N/A12/31/20173,259118N/A944N/A9/30/20173,082114N/A919N/A6/30/20172,948104N/A981N/A3/31/20173,00489N/A776N/A12/31/20162,76467N/A504N/A9/30/20162,64063N/A739N/A6/30/20162,49261N/A558N/A3/31/20162,27958N/A208N/A12/31/20152,16958N/A294N/A9/30/20152,12843N/A-7N/A6/30/20152,05339N/A64N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BEACONPHARの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BEACONPHARの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BEACONPHARの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BEACONPHARの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BEACONPHARの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BEACONPHARの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/15 12:14終値2026/06/15 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Beacon Pharmaceuticals PLC 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 21Beacon Pharmaceuticals PLC to Report Q3, 2026 Results on Apr 27, 2026Beacon Pharmaceuticals PLC announced that they will report Q3, 2026 results on Apr 27, 2026
お知らせ • Jan 22Beacon Pharmaceuticals PLC to Report Q2, 2026 Results on Jan 28, 2026Beacon Pharmaceuticals PLC announced that they will report Q2, 2026 results on Jan 28, 2026
お知らせ • Nov 07Beacon Pharmaceuticals PLC to Report Q1, 2026 Results on Nov 11, 2025Beacon Pharmaceuticals PLC announced that they will report Q1, 2026 results on Nov 11, 2025
お知らせ • Oct 24Beacon Pharmaceuticals PLC announces Annual dividend, payable on January 22, 2026Beacon Pharmaceuticals PLC announced Annual dividend of BDT 2.1000 per share payable on January 22, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.
お知らせ • Oct 23Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2025, at 11:00 Central Asia Standard Time. Location: hybrid platform., Bangladesh
お知らせ • Oct 21Beacon Pharmaceuticals PLC to Report Fiscal Year 2025 Results on Oct 22, 2025Beacon Pharmaceuticals PLC announced that they will report fiscal year 2025 results on Oct 22, 2025
お知らせ • Apr 23Beacon Pharmaceuticals PLC to Report Q3, 2025 Results on Apr 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 20Beacon Pharmaceuticals PLC to Report Q2, 2025 Results on Jan 29, 2025Beacon Pharmaceuticals PLC announced that they will report Q2, 2025 results on Jan 29, 2025
お知らせ • Oct 25Beacon Pharmaceuticals PLC to Report Q1, 2025 Results on Oct 29, 2024Beacon Pharmaceuticals PLC announced that they will report Q1, 2025 results on Oct 29, 2024
Upcoming Dividend • Oct 21Upcoming dividend of ৳2.00 per shareEligible shareholders must have bought the stock before 28 October 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 56% but the company is not cash flow positive. Trailing yield: 1.8%. Lower than top quartile of Bangladeshi dividend payers (4.8%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Oct 07Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ৳113, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 50% over the past three years.
お知らせ • Oct 01Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 23, 2024, at 11:00 Central Asia Standard Time.
お知らせ • Sep 19Beacon Pharmaceuticals PLC to Report Fiscal Year 2024 Results on Sep 29, 2024Beacon Pharmaceuticals PLC announced that they will report fiscal year 2024 results on Sep 29, 2024
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳137, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 37% over the past three years.
Reported Earnings • May 18Third quarter 2024 earnings released: ৳0.95 loss per share (vs ৳0.037 loss in 3Q 2023)Third quarter 2024 results: ৳0.95 loss per share (further deteriorated from ৳0.037 loss in 3Q 2023). Revenue: ৳2.64b (up 23% from 3Q 2023). Net loss: ৳220.3m (loss widened ৳211.6m from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 08Beacon Pharmaceuticals PLC to Report Q3, 2024 Results on May 12, 2024Beacon Pharmaceuticals PLC announced that they will report Q3, 2024 results on May 12, 2024
New Risk • Apr 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Profit margins are more than 30% lower than last year (7.0% net profit margin).
New Risk • Feb 14New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (27% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (7.0% net profit margin).
お知らせ • Jan 30Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company SecretaryBeacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect.
お知らせ • Jan 26Beacon Pharmaceuticals PLC to Report Q2, 2024 Results on Jan 28, 2024Beacon Pharmaceuticals PLC announced that they will report Q2, 2024 results on Jan 28, 2024
Reported Earnings • Jan 25First quarter 2024 earnings released: EPS: ৳1.60 (vs ৳0.99 in 1Q 2023)First quarter 2024 results: EPS: ৳1.60 (up from ৳0.99 in 1Q 2023). Revenue: ৳2.32b (up 15% from 1Q 2023). Net income: ৳369.5m (up 62% from 1Q 2023). Profit margin: 16% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 07Full year 2023 earnings released: EPS: ৳2.21 (vs ৳4.05 in FY 2022)Full year 2023 results: EPS: ৳2.21 (down from ৳4.05 in FY 2022). Revenue: ৳8.51b (up 6.1% from FY 2022). Net income: ৳509.8m (down 46% from FY 2022). Profit margin: 6.0% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (101% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Profit margins are more than 30% lower than last year (8.6% net profit margin).
Upcoming Dividend • Nov 12Upcoming dividend of ৳1.60 per share at 0.7% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 23 January 2024. Payout ratio is a comfortable 39% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%).
お知らせ • Nov 08Beacon Pharmaceuticals PLC to Report Q1, 2024 Results on Nov 13, 2023Beacon Pharmaceuticals PLC announced that they will report Q1, 2024 results on Nov 13, 2023
お知らせ • Oct 26Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023Beacon Pharmaceuticals PLC has recommended 16% Cash Dividend for the year ended June 30, 2023.
お知らせ • Oct 24Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023Beacon Pharmaceuticals PLC, Annual General Meeting, Dec 24, 2023, at 11:00 Bangladesh Standard Time.
お知らせ • Oct 17Beacon Pharmaceuticals PLC to Report Q3, 2023 Results on Oct 22, 2023Beacon Pharmaceuticals PLC announced that they will report Q3, 2023 results on Oct 22, 2023
お知らせ • Jun 20Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial OfficerBeacon Pharmaceuticals PLC announced that the Board of Directors has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023.
お知らせ • May 12+ 1 more updateBeacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFOBeacon Pharmaceuticals PLC informed that Mr. Md. Abdul Haque Sarder, FCS, FCA, CFO of the company resigned from his position with effect from May 09, 2023.
Reported Earnings • May 07Third quarter 2023 earnings released: ৳0.037 loss per share (vs ৳0.99 profit in 3Q 2022)Third quarter 2023 results: ৳0.037 loss per share (down from ৳0.99 profit in 3Q 2022). Revenue: ৳2.15b (up 16% from 3Q 2022). Net loss: ৳8.66m (down 104% from profit in 3Q 2022).
Reported Earnings • Feb 17Second quarter 2023 earnings released: EPS: ৳1.61 (vs ৳1.07 in 2Q 2022)Second quarter 2023 results: EPS: ৳1.61 (up from ৳1.07 in 2Q 2022). Revenue: ৳2.19b (up 5.5% from 2Q 2022). Net income: ৳370.9m (up 51% from 2Q 2022). Profit margin: 17% (up from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Dec 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mohammad Sanaullah was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 24First quarter 2023 earnings released: EPS: ৳0.99 (vs ৳1.52 in 1Q 2022)First quarter 2023 results: EPS: ৳0.99 (down from ৳1.52 in 1Q 2022). Revenue: ৳2.02b (down 11% from 1Q 2022). Net income: ৳228.8m (down 35% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Oct 27Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 16% cash dividend for the year ended on June 30, 2022.
Valuation Update With 7 Day Price Move • Sep 25Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ৳315, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,087% over the past three years.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 24% share price gain to ৳320, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 1,040% over the past three years.
Reported Earnings • May 22Third quarter 2022 earnings released: EPS: ৳0.99 (vs ৳2.01 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.99 (down from ৳2.01 in 3Q 2021). Revenue: ৳1.84b (down 29% from 3Q 2021). Net income: ৳228.9m (down 51% from 3Q 2021). Profit margin: 12% (down from 18% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Director Mohammad Karim was the last director to join the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 12Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳1.07 (up from ৳1.02 in 2Q 2021). Revenue: ৳2.08b (down 4.8% from 2Q 2021). Net income: ৳246.3m (up 5.1% from 2Q 2021). Profit margin: 12% (up from 11% in 2Q 2021). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Dec 14Upcoming dividend of ৳1.50 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 30 January 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.8%).
Reported Earnings • Jun 24Third quarter 2020 earnings released: EPS ৳0.25 (vs ৳0.20 in 3Q 2019)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Feb 25New 90-day high: ৳103The company is up 50% from its price of ৳68.20 on 26 November 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period.
Is New 90 Day High Low • Feb 01New 90-day high: ৳84.30The company is up 5.0% from its price of ৳80.00 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.
Is New 90 Day High Low • Nov 30New 90-day low: ৳66.50The company is down 17% from its price of ৳79.80 on 01 September 2020. The Bangladeshi market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Reported Earnings • Nov 26Third quarter 2020 earnings released: EPS ৳0.25The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳1.37b (up 18% from 3Q 2019). Net income: ৳58.7m (up 24% from 3Q 2019). Profit margin: 4.3% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 07Beacon Pharmaceuticals Ltd. to Report Q3, 2020 Results on Jun 25, 2020Beacon Pharmaceuticals Ltd. announced that they will report Q3, 2020 results on Jun 25, 2020